Equities

Sareum Holdings PLC

Sareum Holdings PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)23.75
  • Today's Change-3.00 / -11.21%
  • Shares traded6.44m
  • 1 Year change-76.83%
  • Beta-1.0380
Data delayed at least 20 minutes, as of Apr 19 2024 17:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Apr-23
  • 18-Jan-24
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
Select bar for recommendation details.
Recommendations18-Apr-24
Buy1
Outperform0
Hold0
Underperform0
Sell0

Share price forecast in GBX

The one analyst offering a 12 month price target expects Sareum Holdings Plc share price to rise to 176.00 in the next year from the last price of 26.75.
High557.9%176.00
Med557.9%176.00
Low557.9%176.00

Earnings history & estimates in GBX

Sareum Holdings Plc reported annual 2023 losses of -4.70 per share on Oct 09, 2023.
Average growth rate-37.44%
More ▼

Revenue history & estimates in GBP

Sareum Holdings plc did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate-33.33%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.